E 4767

Drug Profile

E 4767

Latest Information Update: 15 Feb 2002

Price : $50

At a glance

  • Originator Esteve
  • Class Antibacterials; Fluoroquinolones
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Bacterial infections

Most Recent Events

  • 15 Feb 2002 An in vitro study has been added to the Bacterial infections antimicrobial section
  • 07 Oct 1998 Suspended-I for Bacterial infections in Spain (Unknown route)
  • 25 Aug 1997 Phase-I clinical trials for Bacterial infections in Spain (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top